The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Cannabis in Rheumatology Care: A Look at the Latest Research & What Rheumatologists Are Telling Their Patients

Cannabis in Rheumatology Care: A Look at the Latest Research & What Rheumatologists Are Telling Their Patients

March 26, 2018 • By Carina Stanton

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Regulatory Developments in Europe
In March 2017, it became legal to prescribe 14 strains of cannabis in Germany, which is also seeing an increase in patient requests for cannabis prescriptions, according to Winfried Häuser, MD, a professor of psychosomatic medicine, at the Technical University of Munich and a regular contributor on published research addressing cannabinoids with Dr. Fitzcharles and Dr. Clauw.

You Might Also Like
  • Medical Cannabis Helps Chronic Pain Patients Cut Opioid Use
  • Medical Marijuana Use by Rheumatology Patients Needs Closer Look
  • Little Evidence Shows Cannabis Helps Chronic Pain or PTSD
Explore This Issue
April 2018
Also By This Author
  • 3 Tips for Financial Discussions with Patients

With medicinal cannabis now legal in Germany, patients who meet specific criteria and are prescribed marijuana are being tracked through a registry by Germany’s Federal Institute for Drugs and Medical Devices, with all patient-identifying information removed. Dr. Häuser believes these data could be valuable to better understand the patient populations using medicinal herbal cannabis. He is also working to receive funding from pharmaceutical companies and a public foundation in Germany to further explore cannabis use for chronic pain.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Beyond Germany, Dr. Häuser is working with colleagues across Europe as head of the task force of the European Pain Federation (EFIC) to establish a position statement on the application of cannabis-based medicines to treat chronic pain. He recently co-authored a survey published in the European Journal of Pain that highlights the availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe.8

“[Although] there are marked differences between the countries represented in EFIC in the approval and availability of cannabis-based products for medical use, there is one commonality: There is a significant gap between the public perception of the effectiveness and the safety of cannabis for medical use,” Dr. Häuser asserts.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

What Patients Need to Know
“Patients need to understand that the rheumatology community is actively seeking clinical data to better understand the safe application of cannabinoids for pain management,” Dr. Clauw stresses.

For patients who do choose to use medicinal cannabis, Dr. Clauw and Dr. Fitzcharles make the following suggestions:

  1. Don’t smoke it;
  2. Know the THC level, and choose an application with low THC and high CBD;
  3. Look for a low dose (e.g., 0.5 g at nighttime) because it may be more effective;
  4. Understand that cannabis impairs mobility, and don’t drive for 24 hours after taking it; and
  5. Understand that turning only to marijuana for pain management may set your treatment back to square one. Consider it more for intermittent use, such as during periods of distress/flare.

“There’s no question that cannabinoids are here to stay,” Dr. Fitzcharles says. With the popularity and increased marketing of cannabis products, she fears that people may incorrectly view cannabis as a panacea. “Like any drug, cannabinoids offer opportunities for clinical application, and we would be remiss not to explore those opportunities. However, the barriers to studying cannabinoids in clinical applications may require us to be innovative in moving research forward.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Drug Updates Tagged With: cannabinoid, cannabis, Legal, marijuana, medical marijuanaIssue: April 2018

You Might Also Like:
  • Medical Cannabis Helps Chronic Pain Patients Cut Opioid Use
  • Medical Marijuana Use by Rheumatology Patients Needs Closer Look
  • Little Evidence Shows Cannabis Helps Chronic Pain or PTSD
  • Marijuana for Rheumatology Patients?

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)